FIXED FIVE-YEAR COHORT AUDIT
近五年文献重新检索与对照
旧查询复现与严格 v3 为主比较;历史库存和广召回仅用于解释差异与检查漏检。
固定日期2021-07-29 至 2026-07-29
入排版本oncology-definitive-rct-km-v3
并集论文20925
批次键five-year-20210729-20260729-v1
四个独立队列
数字为批次中保存的原始 PMID 数,不会随着日常监测改变。
集合关系
交集和差集均按 PMID 精确计算;DOI 只用于明细核对。
严格查询未命中、但影子组经 v3 筛选后合格
166 篇
KM 证据
仅检查 v3 元数据合格论文,不运行曲线数字化。
论文明细
共 8933 篇;可组合筛选集合关系、入排结果和 KM 证据。
| 论文 | 队列 | 集合关系 | v3 入排 | KM 证据 |
|---|---|---|---|---|
| Baseline Liquid Biopsy in Relation to Tissue-Based Parameters in Metastatic Colorectal Cancer: Results From the Randomized FIRE-4 (AIO-KRK-0114) Study. PMID 39903881 · J Clin Oncol · 2025-Apr-20 The record describes an original primary result report of a randomized trial with drug interventions and time-to-event efficacy endpoints in human oncology. While the explicit 'Phase III' label is not present in the provided metadata, the trial's scale, design, and publication in a major journal meet the criteria for a definitive randomized trial eligible for this adjudication. |
B
|
影子组漏检补回 | eligiblemodel_adjudicated_eligible | needs_review 0 Figure · 0 Panel · risk not_assessed |
| Postoperative Radiotherapy ± Cetuximab for Intermediate-Risk Head and Neck Cancer. PMID 39841939 · J Clin Oncol · 2025-Apr-20 Eligible as a primary report of a randomized Phase III trial in human oncology with a drug intervention and time-to-event efficacy endpoints. |
B
|
影子组漏检补回 | eligiblemodel_adjudicated_eligible | confirmed 4 Figure · 4 Panel · risk visible |
| Randomized Comparison of Magnetic Resonance Imaging Versus Transurethral Resection for Staging New Bladder Cancers: Results From the Prospective BladderPath Trial. PMID 39808757 · J Clin Oncol · 2025-Apr-20 The study is a randomized, oncology trial in humans comparing two diagnostic/staging pathways (mpMRI vs. TURBT) for bladder cancer. It reports a time-to-event endpoint (Time to Correct Treatment). However, it is excluded because the intervention is non-drug (diagnostic/procedural), not a drug-containing therapy. The time-to-event endpoint is not a standard efficacy endpoint like OS or PFS but a process-of-care measure. No drug intervention is present. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Adjuvant dendritic cell-based immunotherapy in melanoma: insights into immune cell dynamics and clinical evidence from a phase II trial. PMID 40251644 · J Transl Med · 2025-Apr-18 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| A study protocol for the CHinA National CancEr screening (CHANCES) trial: a randomized controlled study to compare the screening strategies for lung cancer and colorectal cancer. PMID 40247218 · BMC Cancer · 2025-Apr-17 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Short-term outcomes of KangDuo surgical robot- versus Da Vinci surgical robot-assisted radical resection of colorectal cancer: a prospective cohort study. PMID 40241095 · BMC Surg · 2025-Apr-16 干预为非药物单独策略,未满足药物干预要求。 |
B
|
仅广召回影子组 | excludednon_drug_intervention | pending 0 Figure · 0 Panel · risk - |
| Physical rehabilitation program for cardiorespiratory health and quality of life among breast cancer survivors in UAE: a randomized control trial. PMID 40241061 · BMC Cancer · 2025-Apr-16 The study is an oncology randomized controlled trial with original results, but it is a physical rehabilitation program (non-drug only) and the primary endpoints are cardiorespiratory fitness and quality of life, not a time-to-event efficacy endpoint. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Impact of lenalidomide consolidation on health-related quality of life in chronic lymphocytic leukemia: ancillary study of the phase III CLL6-RESIDUUM trial. PMID 40240989 · BMC Cancer · 2025-Apr-16 This is an ancillary quality-of-life analysis of a Phase III RCT in chronic lymphocytic leukemia. While the parent trial is eligible for inclusion, this specific report focuses solely on HRQoL outcomes, which are excluded per the adjudication rules (non-efficacy endpoint). No time-to-event efficacy endpoint is reported or signaled in this abstract. |
H
L
B
|
旧查询独有 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Interventions to Reduce Serum Per- and Poly-Fluoroalkyl Substances Levels, Improve Cardiovascular Risk Profiles, and Improve Epigenetic Age Acceleration in US Firefighters: Protocol for Randomized Controlled Trial. PMID 40239196 · JMIR Res Protoc · 2025-Apr-16 The study is not an oncology trial; it is an occupational health intervention trial in firefighters focused on reducing PFAS levels and cardiovascular risk. It is a protocol for a randomized trial, not an original result report. The interventions (blood/plasma donation, physical activity, fasting) are non-pharmacologic. No time-to-event efficacy endpoint (OS, PFS, etc.) is described. The publication type is 'Clinical Trial Protocol'. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Vaccines for preventing infections in adults with solid tumours. PMID 40237463 · Cochrane Database Syst Rev · 2025-Apr-16 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
B
|
仅广召回影子组 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Impact of early multidisciplinary team interventions on dietary management behavior in breast cancer patients: a pilot randomized controlled trial. PMID 40234862 · BMC Cancer · 2025-Apr-15 The study is a randomized oncology trial with a drug-containing intervention (chemotherapy), but it is not a Phase III/IIIb or Phase II/III trial, and its primary endpoints are not time-to-event efficacy measures. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Distinct CD8+ T cell dynamics associate with response to neoadjuvant cancer immunotherapies. PMID 40086437 · Cancer Cell · 2025-Apr-14 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Effect of invitation to colonoscopy versus faecal immunochemical test screening on colorectal cancer mortality (COLONPREV): a pragmatic, randomised, controlled, non-inferiority trial. PMID 40158525 · Lancet · 2025-Apr-12 The trial is an oncology screening study comparing non-drug interventions (colonoscopy vs. faecal immunochemical test). The primary endpoint is colorectal cancer mortality at 10 years, which is a binary outcome (risk difference/RR), not a time-to-event endpoint with survival analysis (Kaplan-Meier or HR). No drug intervention is present. Therefore, it does not meet the criteria for a drug-containing intervention with a primary/key secondary time-to-event efficacy endpoint. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| A study protocol for a double-blinded, randomised, placebo-controlled trial on the use of encapsulated FMT for reducing the side effects of HSCT: the HSCT-BIOME study. PMID 40211191 · BMC Cancer · 2025-Apr-10 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Trastuzumab Plus Pertuzumab Versus Cetuximab Plus Irinotecan in Patients With RAS/BRAF Wild-Type, HER2-Positive, Metastatic Colorectal Cancer (S1613): A Randomized Phase II Trial. PMID 39761503 · J Clin Oncol · 2025-Apr-10 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Mediators of Filgotinib Treatment Effects in Ulcerative Colitis: Exploring Circulating Biomarkers in the Phase 2b/3 SELECTION Study. PMID 39656830 · Inflamm Bowel Dis · 2025-Apr-10 The study is a randomized Phase 2b/3 trial with a drug intervention (filgotinib) and is an original research report. However, it is not an oncology study; it investigates ulcerative colitis. Furthermore, the primary endpoints are biomarker changes and clinical scores, not time-to-event endpoints like OS, PFS, etc. Therefore, it does not meet the criteria for inclusion in the oncology Kaplan-Meier digitization cohort. |
H
L
B
|
旧查询独有 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Efficacy and safety of daratumumab in intermediate/high-risk smoldering multiple myeloma: final analysis of CENTAURUS. PMID 39652826 · Blood · 2025-Apr-10 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Isatuximab, Lenalidomide, Bortezomib, and Dexamethasone Induction Therapy for Transplant-Eligible Newly Diagnosed Multiple Myeloma: Final Part 1 Analysis of the GMMG-HD7 Trial. PMID 39652594 · J Clin Oncol · 2025-Apr-10 The record describes a randomized trial with a time-to-event endpoint (PFS) and a drug intervention, which meets most criteria. However, the phase is not explicitly confirmed as Phase III/IIIb or Phase II/III in the provided metadata (title, abstract, publication types, or deterministic review). The deterministic review flagged 'phase3_evidence_unclear' due to lack of explicit Phase III evidence in PubMed metadata. Since the phase cannot be established from the provided information, the trial is ineligible for the Kaplan-Meier digitization cohort. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Concomitant Administration of Ozanimod and Serotonergic Antidepressants in Patients With Ulcerative Colitis or Relapsing Multiple Sclerosis. PMID 39018016 · Inflamm Bowel Dis · 2025-Apr-10 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
B
|
旧查询独有 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Trusted health system implementation strategies to increase vaccination (TRUE SYNERGI): a stepped-wedge cluster randomized trial to reduce HPV-related cancers. PMID 40205591 · BMC Public Health · 2025-Apr-09 This is a protocol for an implementation science study (stepped-wedge cluster randomized trial) testing strategies to increase HPV vaccination rates in primary care settings. While oncology-related (prevention of HPV-related cancers), it does not meet the core eligibility criteria: it is not a drug-containing intervention (vaccine is preventive, not therapeutic), it is a protocol without results, and the primary endpoint is not a time-to-event efficacy outcome (e.g., OS, PFS, DFS). |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| "There's a lot of unknowns": a thematic analysis of the experiences of young adults with cancer who died during a psychosocial intervention trial. PMID 40205419 · BMC Palliat Care · 2025-Apr-09 The record describes a qualitative thematic analysis of patient experiences from a psychosocial intervention RCT. While it is an oncology RCT involving humans, it fails eligibility because: 1) The intervention is psychosocial, not drug-containing. 2) There is no time-to-event efficacy endpoint (e.g., OS, PFS, KM, HR). 3) The report type is a secondary/subgroup qualitative analysis, not the primary or definitive result of a Phase III drug trial. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Epidemiological Analysis of Obesity-related co-morbidities and mortality among post- menopausal women diagnosed with endometrial cancer: A Randomized Controlled Trial. PMID 40297687 · Res Sq · 2025-Apr-08 Study is an epidemiological analysis of comorbidities and mortality in endometrial cancer patients from the WHI, but does not involve a drug intervention as a key component. While it uses time-to-event methodology (Cox regression), it fails the core requirement of having a drug-containing intervention. The randomized trial nature refers to the WHI trial structure, but the analysis is observational within that context. Phase information is not explicitly provided. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Topical tacrolimus for the amelioration of breast cancer-related lymphedema (TACLE Trial): a study protocol for a randomized, double-blind, placebo-controlled phase II/III trial. PMID 40200322 · Trials · 2025-Apr-08 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Adjuvant TRastuzumab deruxtecan plus fluoropyrimidine versus standard chemotherapy in HER2-positive gastric or gastroesophageal cancer patients with persistence of minimal residual disease in liquid biopsy after pre-operative chemotherapy and radical surgery: the multicentre, phase II randomized TRINITY trial. PMID 40200187 · BMC Cancer · 2025-Apr-08 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Vitamin D supplementation vs. placebo and incident type 2 diabetes in an ancillary study of the randomized Vitamin D and Omega-3 Trial. PMID 40199888 · Nat Commun · 2025-Apr-08 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
B
|
仅广召回影子组 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Bevacizumab, tislelizumab and nab-paclitaxel for previously untreated metastatic triple-negative breast cancer: a phase II trial. PMID 40199609 · J Immunother Cancer · 2025-Apr-08 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Six-month rituximab-lenalidomide regimen in advanced untreated follicular lymphoma: SAKK 35/10 trial 10-year update. PMID 39883948 · Blood Adv · 2025-Apr-08 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Safety and efficacy of filgotinib in Japanese patients with rheumatoid arthritis: Week 156 interim results in FINCH 4. PMID 39506562 · Mod Rheumatol · 2025-Apr-08 The record describes a randomized, Phase 3 trial of a drug (filgotinib) in humans, but the disease is rheumatoid arthritis, which is not oncology. Furthermore, the primary endpoint is not a time-to-event efficacy endpoint (it reports safety and clinical remission). |
H
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Assessing the impact of an intensive dietitian-led telehealth intervention focusing on nutritional adequacy, symptom control and optional supplemental jejunal feeding, on quality of life in patients with pancreatic cancer: a randomised controlled trial protocol. PMID 40197383 · Nutr J · 2025-Apr-07 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Reirradiation based on diffusion-weighted magnetic resonance imaging-guided dose- painting for locally advanced recurrent nasopharyngeal carcinoma: a phase 2 randomized controlled trial. PMID 40197313 · BMC Cancer · 2025-Apr-07 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Digital Health Intervention to Reduce Malnutrition Among Individuals With Gastrointestinal Cancer Receiving Cytoreductive Surgery Combined With Hyperthermic Intraperitoneal Chemotherapy: Feasibility, Acceptability, and Usability Trial. PMID 40194318 · JMIR Cancer · 2025-Apr-07 This is a single-arm feasibility study of a digital health intervention for malnutrition in GI cancer patients, not a randomized Phase III trial with a drug intervention and a time-to-event endpoint. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Vaccination Against RhoC in Prostate Cancer Patients Induces Potent and Long-Lasting CD4+ T Cell Responses with Cytolytic Potential in the Absence of Clinical Efficacy: A Randomized Phase II Trial. PMID 40333248 · Vaccines (Basel) · 2025-Apr-05 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Gain-Framed Text Messages and Nicotine Replacement Therapy for Smoking Cessation Among Lung Cancer Screening Patients: A Brief Report of a Pilot Randomized Controlled Trial. PMID 40283767 · Int J Environ Res Public Health · 2025-Apr-02 The study is an oncology randomized controlled trial but is a pilot study (not Phase III or definitive) and the intervention (smoking cessation with NRT) is not a drug treatment for the malignancy itself; it lacks a primary time-to-event efficacy endpoint for cancer. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Wise or wide (WoW) study protocol: a national, multicentre, prospective, randomised and controlled, parallel group, non-inferiority study to compare single-staged versus two-staged excisions of thin invasive (≤1.0 mm) melanoma. PMID 40180392 · BMJ Open · 2025-Apr-02 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Feasibility of an exercise program in endocrine-treated metastatic breast cancer patients with overweight: protocol for the FEMA study. PMID 40176194 · Pilot Feasibility Stud · 2025-Apr-02 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| IPD regimen effect on the levels of VEGF and IL-6 in elderly patients with recurrent multiple myeloma. PMID 40788733 · Indian J Cancer · 2025-Apr-01 The study meets most eligibility criteria: it is an oncology, human, randomized trial with drug intervention, time-to-event (PFS) analysis, and original results. However, the explicit trial phase (Phase III/IIIb or Phase II/III) is not confirmed in the available metadata. Therefore, the 'phase3_or_definitive' criterion cannot be set to true, leading to ineligibility. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| A prospective comparative study of pre-op chemoradiotherapy followed by surgery versus upfront surgery followed by adjuvant chemoradiotherapy in locally advanced borderline resectable oral cavity cancer. PMID 40616538 · J Cancer Res Ther · 2025-Apr-01 The study is a randomized trial in oncology with a drug intervention, but the provided metadata does not confirm it as a Phase III or Phase II/III trial. Furthermore, the reported primary endpoints are pathological and surgical outcomes, not a time-to-event efficacy endpoint like OS or DFS, which are required for inclusion. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Clinical Trial Notifications Triggered by Artificial Intelligence-Detected Cancer Progression: A Randomized Trial. PMID 40257799 · JAMA Netw Open · 2025-Apr-01 The study is a randomized trial in human oncology with a drug intervention (clinical trials as the intervention), but it lacks a time-to-event efficacy endpoint and does not explicitly test a drug intervention in the arms. The primary outcome is trial enrollment rate, not OS/PFS/DFS/EFS/RFS/TTP or any other time-to-event measure. No Kaplan-Meier curves or hazard ratios are reported. The study is not a Phase III/IIIb or Phase II/III randomized trial of a drug intervention with time-to-event endpoints. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Lung Cancer Surveillance for Patients With Head and Neck Cancer. PMID 40048159 · JAMA Otolaryngol Head Neck Surg · 2025-Apr-01 The record is for a randomized trial in head and neck cancer with overall survival and disease-free survival as secondary outcomes, but it does not involve a drug-containing intervention (comparing imaging modalities). The trial phase is not explicitly stated in the provided metadata, so it cannot be confirmed as Phase III/IIIb or Phase II/III. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Risk factors for anastomotic leakage and its impact on survival outcomes in radical multivisceral surgery for advanced ovarian cancer: an AGO-OVAR.OP3/LION exploratory analysis. PMID 39992106 · Int J Surg · 2025-Apr-01 The record is from a Phase III randomized trial with time-to-event endpoints, but the intervention is purely surgical (lymphadenectomy). There is no drug-containing intervention, which is a required criterion for eligibility. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Tumor-Infiltrating Lymphocytes and Survival Outcomes in Early ERBB2-Positive Breast Cancer: 10-Year Analysis of the ShortHER Randomized Clinical Trial. PMID 39946142 · JAMA Oncol · 2025-Apr-01 The record is a subgroup/biomarker analysis of a randomized trial with drug intervention and time-to-event endpoints, but the trial phase is not explicitly stated as Phase III/IIIb or Phase II/III in the provided metadata, and the primary focus is on TILs subgroup effects, not the overall trial primary efficacy result. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| An updated systematic review, meta-analysis, and trial sequential analysis of the efficacy and safety of en bloc transurethral resection vs. conventional transurethral resection for nonmuscle-invasive bladder tumor. PMID 39927777 · Int J Surg · 2025-Apr-01 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
B
|
仅广召回影子组 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Anlotinib versus Placebo as Adjuvant Therapy for Localized High-Grade Soft-Tissue Sarcomas: A Phase II, Double-Blinded, Randomized Controlled Trial. PMID 39918552 · Clin Cancer Res · 2025-Apr-01 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Pembrolizumab in Patients With Advanced Clear Cell Gynecological Cancer: A Phase 2 Nonrandomized Clinical Trial. PMID 39913118 · JAMA Oncol · 2025-Apr-01 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Endothelial Cell pY397-FAK Expression Predicts the Risk of Breast Cancer Recurrences after Radiotherapy in the SweBCG91-RT Cohort. PMID 39908003 · Clin Cancer Res · 2025-Apr-01 The study meets criteria for oncology, human, randomized, original report with time-to-event analysis. However, it is excluded because the intervention is non-drug-only (radiotherapy), lacking a drug-containing intervention as required. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Tislelizumab combined with nab-paclitaxel and cisplatin as the more effective chemoimmunotherapy strategy in the neoadjuvant treatment of locally advanced thoracic esophageal squamous cell carcinoma: A prospective, two-cohort, phase 2 trial. PMID 39686540 · Int J Cancer · 2025-Apr-01 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Patient-reported outcomes in randomized controlled trials evaluating BRAF inhibitors in patients with cutaneous melanoma: a systematic scoping review of quality of reporting and trial results. PMID 39668671 · Melanoma Res · 2025-Apr-01 The record is a systematic scoping review of PRO reporting in trials, not an original trial report with primary/key secondary time-to-event efficacy results. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Phase II Randomized Controlled Trial to Evaluate the Supportive Effect of Koujin (TJ-3020) Powder in Gemcitabine and Nab-Paclitaxel-Treated Unresectable or Recurrent Pancreatic Cancer. PMID 39626189 · Pancreas · 2025-Apr-01 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Toxicity and Efficacy of Different Target Volume Delineations of Radiation Therapy Based on the Updated Radiation Therapy Oncology Group/National Research Group and European Organization for Research and Treatment of Cancer Guidelines in Patients With Grade 3-4 Glioma: A Randomized Controlled Clinical Trial. PMID 39615657 · Int J Radiat Oncol Biol Phys · 2025-Apr-01 The study is a randomized, human, oncology trial reporting time-to-event efficacy endpoints (PFS, OS). However, it is excluded because the intervention does not include a drug-containing arm (both arms receive identical temozolomide; the comparison is of radiation guidelines, not a drug) and the trial phase is not explicitly stated as Phase III/IIIb or Phase II/III in the provided metadata. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Survival Without Quality of Life Deterioration in the GORTEC 2014-04 "OMET" Randomized Phase 2 Trial in Patients with Head and Neck Cancer with Oligometastases using Stereotactic Ablative Radiation Therapy (SABR) alone or Chemotherapy and SABR. PMID 39612953 · Int J Radiat Oncol Biol Phys · 2025-Apr-01 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |